Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score Article Swipe
Fiona Fernando
,
María Sol Andrés
,
Simone Claudiani
,
Nazanin Zounemat Kermani
,
Giulia Ceccarelli
,
Andrew J. Innes
,
Afzal Khan
,
Stuart D. Rosen
,
Jane F. Apperley
,
Alexander R Lyon
,
Dragana Milojković
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1186/s40959-024-00245-x
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1186/s40959-024-00245-x
Background The therapeutic landscape of chronic myeloid leukaemia (CML) has been transformed by tyrosine kinase inhibitors (TKI). Nilotinib, showed higher rates of major molecular response than imatinib, however associated with higher cardiovascular (CV) toxicity. We sought to describe the CV events associated with nilotinib in a real-world population and assess the predictive value of the HFA-ICOS risk score. Methods The HFA-ICOS baseline risk was calculated for patients with CML treated with nilotinib beween 2006 and 2021. The primary end point was the incidence of all CV events. The secondary end point was the incidence of ischaemic events. Survival analysis evaluated the risk (hazard ratio [HR]) of events stratified by baseline risk category, whilst on nilotinib therapy. Results Two hundred and twenty-nine eligible patients were included. The incidence of CV events was 20.9% (95% CI: 15.7–26.2%) following a median duration of treatment of 34.4 months. The secondary end point occurred in 12.7% (95% CI: 8.4–16.9%) of the population. Patients with higher HFA-ICOS baseline score had higher rates of CV events (low: 11.2%, medium: 28.2% [HR: 2.51, 95% CI: 1.17–5.66], high/very high: 32.4% [HR: 3.57, 95% CI: 1.77–7.20]) and ischaemic events (low: 5.20%, medium: 17.9% [HR: 2.19, 95% CI: 0.97–4.96], high/very high: 21.6% [HR: 3.9, 95% CI: 1.91–7.89]). In patients who did not have a CV event, the median total dose at last follow up or cessation of nilotinib therapy was lower when compared to the total daily median dose of nilotinib in patients who had a CV event (450 mg vs. 600 mg, p = 0.0074). Conclusions The HFA-ICOS risk stratification tool is an efficient discriminator at low, medium and high/very high risk of developing cardiovascular events, with an overall positive trend towards increasing cardiotoxicity rates with rising risk catergories. This study provides evidence to support the use of this predictive tool in nilotinib treated patients.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1186/s40959-024-00245-x
- https://cardiooncologyjournal.biomedcentral.com/counter/pdf/10.1186/s40959-024-00245-x
- OA Status
- gold
- Cited By
- 5
- References
- 21
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4400658937
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4400658937Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1186/s40959-024-00245-xDigital Object Identifier
- Title
-
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk scoreWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-07-15Full publication date if available
- Authors
-
Fiona Fernando, María Sol Andrés, Simone Claudiani, Nazanin Zounemat Kermani, Giulia Ceccarelli, Andrew J. Innes, Afzal Khan, Stuart D. Rosen, Jane F. Apperley, Alexander R Lyon, Dragana MilojkovićList of authors in order
- Landing page
-
https://doi.org/10.1186/s40959-024-00245-xPublisher landing page
- PDF URL
-
https://cardiooncologyjournal.biomedcentral.com/counter/pdf/10.1186/s40959-024-00245-xDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://cardiooncologyjournal.biomedcentral.com/counter/pdf/10.1186/s40959-024-00245-xDirect OA link when available
- Concepts
-
Nilotinib, Medicine, Imatinib, Internal medicine, Tyrosine-kinase inhibitor, Chronic myeloid leukaemia, Tyrosine kinase, Framingham Risk Score, Oncology, Population, Predictive value, Myeloid leukemia, Disease, Cancer, Receptor, Environmental healthTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3, 2024: 2Per-year citation counts (last 5 years)
- References (count)
-
21Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4400658937 |
|---|---|
| doi | https://doi.org/10.1186/s40959-024-00245-x |
| ids.doi | https://doi.org/10.1186/s40959-024-00245-x |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39010172 |
| ids.openalex | https://openalex.org/W4400658937 |
| fwci | 4.83098373 |
| type | article |
| title | Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score |
| biblio.issue | 1 |
| biblio.volume | 10 |
| biblio.last_page | 42 |
| biblio.first_page | 42 |
| topics[0].id | https://openalex.org/T11215 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Chronic Myeloid Leukemia Treatments |
| topics[1].id | https://openalex.org/T11535 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9973999857902527 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2705 |
| topics[1].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[1].display_name | Chemotherapy-induced cardiotoxicity and mitigation |
| topics[2].id | https://openalex.org/T12600 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9944999814033508 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2745 |
| topics[2].subfield.display_name | Rheumatology |
| topics[2].display_name | Eosinophilic Disorders and Syndromes |
| is_xpac | False |
| apc_list.value | 1690 |
| apc_list.currency | GBP |
| apc_list.value_usd | 2072 |
| apc_paid.value | 1690 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 2072 |
| concepts[0].id | https://openalex.org/C2777413986 |
| concepts[0].level | 4 |
| concepts[0].score | 0.985639214515686 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q412327 |
| concepts[0].display_name | Nilotinib |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7633781433105469 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2777583451 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7402689456939697 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q177094 |
| concepts[2].display_name | Imatinib |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6347940564155579 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C2778820342 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5488232374191284 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q906415 |
| concepts[4].display_name | Tyrosine-kinase inhibitor |
| concepts[5].id | https://openalex.org/C2993416501 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5474137663841248 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q729735 |
| concepts[5].display_name | Chronic myeloid leukaemia |
| concepts[6].id | https://openalex.org/C42362537 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5193556547164917 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q87099740 |
| concepts[6].display_name | Tyrosine kinase |
| concepts[7].id | https://openalex.org/C11783203 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4913994073867798 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q5478027 |
| concepts[7].display_name | Framingham Risk Score |
| concepts[8].id | https://openalex.org/C143998085 |
| concepts[8].level | 1 |
| concepts[8].score | 0.47630608081817627 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[8].display_name | Oncology |
| concepts[9].id | https://openalex.org/C2908647359 |
| concepts[9].level | 2 |
| concepts[9].score | 0.42898404598236084 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[9].display_name | Population |
| concepts[10].id | https://openalex.org/C3019719930 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4239521920681 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q3910099 |
| concepts[10].display_name | Predictive value |
| concepts[11].id | https://openalex.org/C2778729363 |
| concepts[11].level | 2 |
| concepts[11].score | 0.3063604533672333 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11688946 |
| concepts[11].display_name | Myeloid leukemia |
| concepts[12].id | https://openalex.org/C2779134260 |
| concepts[12].level | 2 |
| concepts[12].score | 0.1547306478023529 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[12].display_name | Disease |
| concepts[13].id | https://openalex.org/C121608353 |
| concepts[13].level | 2 |
| concepts[13].score | 0.08771902322769165 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[13].display_name | Cancer |
| concepts[14].id | https://openalex.org/C170493617 |
| concepts[14].level | 2 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[14].display_name | Receptor |
| concepts[15].id | https://openalex.org/C99454951 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[15].display_name | Environmental health |
| keywords[0].id | https://openalex.org/keywords/nilotinib |
| keywords[0].score | 0.985639214515686 |
| keywords[0].display_name | Nilotinib |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7633781433105469 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/imatinib |
| keywords[2].score | 0.7402689456939697 |
| keywords[2].display_name | Imatinib |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.6347940564155579 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/tyrosine-kinase-inhibitor |
| keywords[4].score | 0.5488232374191284 |
| keywords[4].display_name | Tyrosine-kinase inhibitor |
| keywords[5].id | https://openalex.org/keywords/chronic-myeloid-leukaemia |
| keywords[5].score | 0.5474137663841248 |
| keywords[5].display_name | Chronic myeloid leukaemia |
| keywords[6].id | https://openalex.org/keywords/tyrosine-kinase |
| keywords[6].score | 0.5193556547164917 |
| keywords[6].display_name | Tyrosine kinase |
| keywords[7].id | https://openalex.org/keywords/framingham-risk-score |
| keywords[7].score | 0.4913994073867798 |
| keywords[7].display_name | Framingham Risk Score |
| keywords[8].id | https://openalex.org/keywords/oncology |
| keywords[8].score | 0.47630608081817627 |
| keywords[8].display_name | Oncology |
| keywords[9].id | https://openalex.org/keywords/population |
| keywords[9].score | 0.42898404598236084 |
| keywords[9].display_name | Population |
| keywords[10].id | https://openalex.org/keywords/predictive-value |
| keywords[10].score | 0.4239521920681 |
| keywords[10].display_name | Predictive value |
| keywords[11].id | https://openalex.org/keywords/myeloid-leukemia |
| keywords[11].score | 0.3063604533672333 |
| keywords[11].display_name | Myeloid leukemia |
| keywords[12].id | https://openalex.org/keywords/disease |
| keywords[12].score | 0.1547306478023529 |
| keywords[12].display_name | Disease |
| keywords[13].id | https://openalex.org/keywords/cancer |
| keywords[13].score | 0.08771902322769165 |
| keywords[13].display_name | Cancer |
| language | en |
| locations[0].id | doi:10.1186/s40959-024-00245-x |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210195129 |
| locations[0].source.issn | 2057-3804 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2057-3804 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Cardio-Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310320256 |
| locations[0].source.host_organization_name | BioMed Central |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320256 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://cardiooncologyjournal.biomedcentral.com/counter/pdf/10.1186/s40959-024-00245-x |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cardio-Oncology |
| locations[0].landing_page_url | https://doi.org/10.1186/s40959-024-00245-x |
| locations[1].id | pmid:39010172 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cardio-oncology (London, England) |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39010172 |
| locations[2].id | pmh:oai:doaj.org/article:f3fb29a7cf9b43e2b4d17bd6d64a0418 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Cardio-Oncology, Vol 10, Iss 1, Pp 1-10 (2024) |
| locations[2].landing_page_url | https://doaj.org/article/f3fb29a7cf9b43e2b4d17bd6d64a0418 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:11247904 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Cardiooncology |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11247904 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5110508169 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Fiona Fernando |
| authorships[0].countries | GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| authorships[0].affiliations[0].raw_affiliation_string | Haematology department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK |
| authorships[0].institutions[0].id | https://openalex.org/I2801748203 |
| authorships[0].institutions[0].ror | https://ror.org/05jg8yp15 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| authorships[0].institutions[0].country_code | GB |
| authorships[0].institutions[0].display_name | Hammersmith Hospital |
| authorships[0].institutions[1].id | https://openalex.org/I153355300 |
| authorships[0].institutions[1].ror | https://ror.org/056ffv270 |
| authorships[0].institutions[1].type | healthcare |
| authorships[0].institutions[1].lineage | https://openalex.org/I153355300 |
| authorships[0].institutions[1].country_code | GB |
| authorships[0].institutions[1].display_name | Imperial College Healthcare NHS Trust |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Fiona Fernando |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Haematology department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK |
| authorships[1].author.id | https://openalex.org/A5046879492 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9554-2026 |
| authorships[1].author.display_name | María Sol Andrés |
| authorships[1].countries | GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210096640 |
| authorships[1].affiliations[0].raw_affiliation_string | Cardio-Oncology Service, Royal Brompton Hospital, |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I200166805 |
| authorships[1].affiliations[1].raw_affiliation_string | Guy's and St Thomas' NHS Foundation Trust, London, UK |
| authorships[1].institutions[0].id | https://openalex.org/I200166805 |
| authorships[1].institutions[0].ror | https://ror.org/00j161312 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I200166805 |
| authorships[1].institutions[0].country_code | GB |
| authorships[1].institutions[0].display_name | Guy's and St Thomas' NHS Foundation Trust |
| authorships[1].institutions[1].id | https://openalex.org/I4210096640 |
| authorships[1].institutions[1].ror | https://ror.org/00cv4n034 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I2800036501, https://openalex.org/I4210096640 |
| authorships[1].institutions[1].country_code | GB |
| authorships[1].institutions[1].display_name | Royal Brompton Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Maria Sol Andres |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Cardio-Oncology Service, Royal Brompton Hospital,, Guy's and St Thomas' NHS Foundation Trust, London, UK |
| authorships[2].author.id | https://openalex.org/A5009840248 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3686-7610 |
| authorships[2].author.display_name | Simone Claudiani |
| authorships[2].countries | GB |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I47508984 |
| authorships[2].affiliations[0].raw_affiliation_string | Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK |
| authorships[2].institutions[0].id | https://openalex.org/I47508984 |
| authorships[2].institutions[0].ror | https://ror.org/041kmwe10 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I47508984 |
| authorships[2].institutions[0].country_code | GB |
| authorships[2].institutions[0].display_name | Imperial College London |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Simone Claudiani |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK |
| authorships[3].author.id | https://openalex.org/A5057676234 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-2479-3861 |
| authorships[3].author.display_name | Nazanin Zounemat Kermani |
| authorships[3].countries | GB |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I47508984 |
| authorships[3].affiliations[0].raw_affiliation_string | Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK |
| authorships[3].institutions[0].id | https://openalex.org/I47508984 |
| authorships[3].institutions[0].ror | https://ror.org/041kmwe10 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I47508984 |
| authorships[3].institutions[0].country_code | GB |
| authorships[3].institutions[0].display_name | Imperial College London |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Nazanin Zounemat Kermani |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK |
| authorships[4].author.id | https://openalex.org/A5001627271 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Giulia Ceccarelli |
| authorships[4].countries | GB |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| authorships[4].affiliations[0].raw_affiliation_string | Haematology department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK |
| authorships[4].institutions[0].id | https://openalex.org/I2801748203 |
| authorships[4].institutions[0].ror | https://ror.org/05jg8yp15 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| authorships[4].institutions[0].country_code | GB |
| authorships[4].institutions[0].display_name | Hammersmith Hospital |
| authorships[4].institutions[1].id | https://openalex.org/I153355300 |
| authorships[4].institutions[1].ror | https://ror.org/056ffv270 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I153355300 |
| authorships[4].institutions[1].country_code | GB |
| authorships[4].institutions[1].display_name | Imperial College Healthcare NHS Trust |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Giulia Ceccarelli |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Haematology department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK |
| authorships[5].author.id | https://openalex.org/A5031562318 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-0918-8882 |
| authorships[5].author.display_name | Andrew J. Innes |
| authorships[5].countries | GB |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| authorships[5].affiliations[0].raw_affiliation_string | Haematology department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK |
| authorships[5].institutions[0].id | https://openalex.org/I2801748203 |
| authorships[5].institutions[0].ror | https://ror.org/05jg8yp15 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| authorships[5].institutions[0].country_code | GB |
| authorships[5].institutions[0].display_name | Hammersmith Hospital |
| authorships[5].institutions[1].id | https://openalex.org/I153355300 |
| authorships[5].institutions[1].ror | https://ror.org/056ffv270 |
| authorships[5].institutions[1].type | healthcare |
| authorships[5].institutions[1].lineage | https://openalex.org/I153355300 |
| authorships[5].institutions[1].country_code | GB |
| authorships[5].institutions[1].display_name | Imperial College Healthcare NHS Trust |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Andrew J. Innes |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Haematology department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK |
| authorships[6].author.id | https://openalex.org/A5021736218 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-0224-4717 |
| authorships[6].author.display_name | Afzal Khan |
| authorships[6].countries | GB |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| authorships[6].affiliations[0].raw_affiliation_string | Haematology department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK |
| authorships[6].institutions[0].id | https://openalex.org/I2801748203 |
| authorships[6].institutions[0].ror | https://ror.org/05jg8yp15 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| authorships[6].institutions[0].country_code | GB |
| authorships[6].institutions[0].display_name | Hammersmith Hospital |
| authorships[6].institutions[1].id | https://openalex.org/I153355300 |
| authorships[6].institutions[1].ror | https://ror.org/056ffv270 |
| authorships[6].institutions[1].type | healthcare |
| authorships[6].institutions[1].lineage | https://openalex.org/I153355300 |
| authorships[6].institutions[1].country_code | GB |
| authorships[6].institutions[1].display_name | Imperial College Healthcare NHS Trust |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Afzal Khan |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Haematology department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK |
| authorships[7].author.id | https://openalex.org/A5070763687 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-8034-0037 |
| authorships[7].author.display_name | Stuart D. Rosen |
| authorships[7].countries | GB |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I200166805, https://openalex.org/I4210096640 |
| authorships[7].affiliations[0].raw_affiliation_string | Cardio-Oncology Service, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK |
| authorships[7].institutions[0].id | https://openalex.org/I200166805 |
| authorships[7].institutions[0].ror | https://ror.org/00j161312 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I200166805 |
| authorships[7].institutions[0].country_code | GB |
| authorships[7].institutions[0].display_name | Guy's and St Thomas' NHS Foundation Trust |
| authorships[7].institutions[1].id | https://openalex.org/I4210096640 |
| authorships[7].institutions[1].ror | https://ror.org/00cv4n034 |
| authorships[7].institutions[1].type | healthcare |
| authorships[7].institutions[1].lineage | https://openalex.org/I2800036501, https://openalex.org/I4210096640 |
| authorships[7].institutions[1].country_code | GB |
| authorships[7].institutions[1].display_name | Royal Brompton Hospital |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Stuart D. Rosen |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Cardio-Oncology Service, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK |
| authorships[8].author.id | https://openalex.org/A5074115908 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-1710-1794 |
| authorships[8].author.display_name | Jane F. Apperley |
| authorships[8].countries | GB |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I47508984 |
| authorships[8].affiliations[0].raw_affiliation_string | Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK |
| authorships[8].institutions[0].id | https://openalex.org/I47508984 |
| authorships[8].institutions[0].ror | https://ror.org/041kmwe10 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I47508984 |
| authorships[8].institutions[0].country_code | GB |
| authorships[8].institutions[0].display_name | Imperial College London |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Jane F. Apperley |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK |
| authorships[9].author.id | https://openalex.org/A5107844564 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Alexander R Lyon |
| authorships[9].countries | GB |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I200166805, https://openalex.org/I4210096640 |
| authorships[9].affiliations[0].raw_affiliation_string | Cardio-Oncology Service, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK |
| authorships[9].institutions[0].id | https://openalex.org/I200166805 |
| authorships[9].institutions[0].ror | https://ror.org/00j161312 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I200166805 |
| authorships[9].institutions[0].country_code | GB |
| authorships[9].institutions[0].display_name | Guy's and St Thomas' NHS Foundation Trust |
| authorships[9].institutions[1].id | https://openalex.org/I4210096640 |
| authorships[9].institutions[1].ror | https://ror.org/00cv4n034 |
| authorships[9].institutions[1].type | healthcare |
| authorships[9].institutions[1].lineage | https://openalex.org/I2800036501, https://openalex.org/I4210096640 |
| authorships[9].institutions[1].country_code | GB |
| authorships[9].institutions[1].display_name | Royal Brompton Hospital |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Alexander R. Lyon |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Cardio-Oncology Service, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK |
| authorships[10].author.id | https://openalex.org/A5086020780 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-0593-8220 |
| authorships[10].author.display_name | Dragana Milojković |
| authorships[10].countries | GB |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I47508984 |
| authorships[10].affiliations[0].raw_affiliation_string | Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK |
| authorships[10].institutions[0].id | https://openalex.org/I47508984 |
| authorships[10].institutions[0].ror | https://ror.org/041kmwe10 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I47508984 |
| authorships[10].institutions[0].country_code | GB |
| authorships[10].institutions[0].display_name | Imperial College London |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | Dragana Milojkovic |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://cardiooncologyjournal.biomedcentral.com/counter/pdf/10.1186/s40959-024-00245-x |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11215 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Chronic Myeloid Leukemia Treatments |
| related_works | https://openalex.org/W2061860992, https://openalex.org/W3176823109, https://openalex.org/W2252716012, https://openalex.org/W1978588805, https://openalex.org/W2029785773, https://openalex.org/W2314058894, https://openalex.org/W2163329109, https://openalex.org/W2034964376, https://openalex.org/W2432278050, https://openalex.org/W1963599260 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1186/s40959-024-00245-x |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210195129 |
| best_oa_location.source.issn | 2057-3804 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2057-3804 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Cardio-Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320256 |
| best_oa_location.source.host_organization_name | BioMed Central |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320256 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://cardiooncologyjournal.biomedcentral.com/counter/pdf/10.1186/s40959-024-00245-x |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cardio-Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1186/s40959-024-00245-x |
| primary_location.id | doi:10.1186/s40959-024-00245-x |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210195129 |
| primary_location.source.issn | 2057-3804 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2057-3804 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Cardio-Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310320256 |
| primary_location.source.host_organization_name | BioMed Central |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320256 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://cardiooncologyjournal.biomedcentral.com/counter/pdf/10.1186/s40959-024-00245-x |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cardio-Oncology |
| primary_location.landing_page_url | https://doi.org/10.1186/s40959-024-00245-x |
| publication_date | 2024-07-15 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W3119368005, https://openalex.org/W3009751715, https://openalex.org/W2473480037, https://openalex.org/W2740029254, https://openalex.org/W2260921597, https://openalex.org/W3013082751, https://openalex.org/W2010678043, https://openalex.org/W3046714659, https://openalex.org/W3092607363, https://openalex.org/W4294307875, https://openalex.org/W3021092526, https://openalex.org/W3166015112, https://openalex.org/W2769668115, https://openalex.org/W2618596952, https://openalex.org/W3031292493, https://openalex.org/W4386153206, https://openalex.org/W3164908038, https://openalex.org/W4220761738, https://openalex.org/W2011814974, https://openalex.org/W1960354891, https://openalex.org/W4293217281 |
| referenced_works_count | 21 |
| abstract_inverted_index.= | 254 |
| abstract_inverted_index.a | 46, 137, 213, 245 |
| abstract_inverted_index.p | 253 |
| abstract_inverted_index.CV | 40, 86, 129, 168, 214, 246 |
| abstract_inverted_index.In | 207 |
| abstract_inverted_index.We | 35 |
| abstract_inverted_index.an | 263, 278 |
| abstract_inverted_index.at | 220, 266 |
| abstract_inverted_index.by | 13, 109 |
| abstract_inverted_index.in | 45, 150, 241, 302 |
| abstract_inverted_index.is | 262 |
| abstract_inverted_index.mg | 249 |
| abstract_inverted_index.of | 5, 22, 54, 84, 95, 106, 128, 140, 142, 155, 167, 226, 239, 273, 298 |
| abstract_inverted_index.on | 114 |
| abstract_inverted_index.or | 224 |
| abstract_inverted_index.to | 37, 233, 294 |
| abstract_inverted_index.up | 223 |
| abstract_inverted_index.600 | 251 |
| abstract_inverted_index.95% | 176, 184, 196, 204 |
| abstract_inverted_index.CI: | 134, 153, 177, 185, 197, 205 |
| abstract_inverted_index.CML | 69 |
| abstract_inverted_index.The | 2, 60, 77, 88, 126, 145, 257 |
| abstract_inverted_index.Two | 118 |
| abstract_inverted_index.all | 85 |
| abstract_inverted_index.and | 49, 75, 120, 187, 269 |
| abstract_inverted_index.did | 210 |
| abstract_inverted_index.end | 79, 90, 147 |
| abstract_inverted_index.for | 66 |
| abstract_inverted_index.had | 164, 244 |
| abstract_inverted_index.has | 10 |
| abstract_inverted_index.mg, | 252 |
| abstract_inverted_index.not | 211 |
| abstract_inverted_index.the | 39, 51, 55, 82, 93, 101, 156, 216, 234, 296 |
| abstract_inverted_index.use | 297 |
| abstract_inverted_index.vs. | 250 |
| abstract_inverted_index.was | 64, 81, 92, 131, 229 |
| abstract_inverted_index.who | 209, 243 |
| abstract_inverted_index.(450 | 248 |
| abstract_inverted_index.(95% | 133, 152 |
| abstract_inverted_index.(CV) | 33 |
| abstract_inverted_index.2006 | 74 |
| abstract_inverted_index.3.9, | 203 |
| abstract_inverted_index.34.4 | 143 |
| abstract_inverted_index.This | 290 |
| abstract_inverted_index.[HR: | 174, 182, 194, 202 |
| abstract_inverted_index.been | 11 |
| abstract_inverted_index.dose | 219, 238 |
| abstract_inverted_index.have | 212 |
| abstract_inverted_index.high | 271 |
| abstract_inverted_index.last | 221 |
| abstract_inverted_index.low, | 267 |
| abstract_inverted_index.risk | 57, 63, 102, 111, 259, 272, 288 |
| abstract_inverted_index.than | 26 |
| abstract_inverted_index.this | 299 |
| abstract_inverted_index.tool | 261, 301 |
| abstract_inverted_index.were | 124 |
| abstract_inverted_index.when | 231 |
| abstract_inverted_index.with | 30, 43, 68, 71, 159, 277, 286 |
| abstract_inverted_index.(CML) | 9 |
| abstract_inverted_index.(low: | 170, 190 |
| abstract_inverted_index.12.7% | 151 |
| abstract_inverted_index.17.9% | 193 |
| abstract_inverted_index.2.19, | 195 |
| abstract_inverted_index.2.51, | 175 |
| abstract_inverted_index.20.9% | 132 |
| abstract_inverted_index.2021. | 76 |
| abstract_inverted_index.21.6% | 201 |
| abstract_inverted_index.28.2% | 173 |
| abstract_inverted_index.3.57, | 183 |
| abstract_inverted_index.32.4% | 181 |
| abstract_inverted_index.[HR]) | 105 |
| abstract_inverted_index.daily | 236 |
| abstract_inverted_index.event | 247 |
| abstract_inverted_index.high: | 180, 200 |
| abstract_inverted_index.lower | 230 |
| abstract_inverted_index.major | 23 |
| abstract_inverted_index.point | 80, 91, 148 |
| abstract_inverted_index.rates | 21, 166, 285 |
| abstract_inverted_index.ratio | 104 |
| abstract_inverted_index.score | 163 |
| abstract_inverted_index.study | 291 |
| abstract_inverted_index.total | 218, 235 |
| abstract_inverted_index.trend | 281 |
| abstract_inverted_index.value | 53 |
| abstract_inverted_index.(TKI). | 17 |
| abstract_inverted_index.11.2%, | 171 |
| abstract_inverted_index.5.20%, | 191 |
| abstract_inverted_index.assess | 50 |
| abstract_inverted_index.beween | 73 |
| abstract_inverted_index.event, | 215 |
| abstract_inverted_index.events | 41, 107, 130, 169, 189 |
| abstract_inverted_index.follow | 222 |
| abstract_inverted_index.higher | 20, 31, 160, 165 |
| abstract_inverted_index.kinase | 15 |
| abstract_inverted_index.median | 138, 217, 237 |
| abstract_inverted_index.medium | 268 |
| abstract_inverted_index.rising | 287 |
| abstract_inverted_index.score. | 58 |
| abstract_inverted_index.showed | 19 |
| abstract_inverted_index.sought | 36 |
| abstract_inverted_index.whilst | 113 |
| abstract_inverted_index.(hazard | 103 |
| abstract_inverted_index.Methods | 59 |
| abstract_inverted_index.Results | 117 |
| abstract_inverted_index.chronic | 6 |
| abstract_inverted_index.events, | 276 |
| abstract_inverted_index.events. | 87, 97 |
| abstract_inverted_index.however | 28 |
| abstract_inverted_index.hundred | 119 |
| abstract_inverted_index.medium: | 172, 192 |
| abstract_inverted_index.months. | 144 |
| abstract_inverted_index.myeloid | 7 |
| abstract_inverted_index.overall | 279 |
| abstract_inverted_index.primary | 78 |
| abstract_inverted_index.support | 295 |
| abstract_inverted_index.therapy | 228 |
| abstract_inverted_index.towards | 282 |
| abstract_inverted_index.treated | 70, 304 |
| abstract_inverted_index.0.0074). | 255 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.HFA-ICOS | 56, 61, 161, 258 |
| abstract_inverted_index.Patients | 158 |
| abstract_inverted_index.Survival | 98 |
| abstract_inverted_index.analysis | 99 |
| abstract_inverted_index.baseline | 62, 110, 162 |
| abstract_inverted_index.compared | 232 |
| abstract_inverted_index.describe | 38 |
| abstract_inverted_index.duration | 139 |
| abstract_inverted_index.eligible | 122 |
| abstract_inverted_index.evidence | 293 |
| abstract_inverted_index.occurred | 149 |
| abstract_inverted_index.patients | 67, 123, 208, 242 |
| abstract_inverted_index.positive | 280 |
| abstract_inverted_index.provides | 292 |
| abstract_inverted_index.response | 25 |
| abstract_inverted_index.therapy. | 116 |
| abstract_inverted_index.tyrosine | 14 |
| abstract_inverted_index.category, | 112 |
| abstract_inverted_index.cessation | 225 |
| abstract_inverted_index.efficient | 264 |
| abstract_inverted_index.evaluated | 100 |
| abstract_inverted_index.following | 136 |
| abstract_inverted_index.high/very | 179, 199, 270 |
| abstract_inverted_index.imatinib, | 27 |
| abstract_inverted_index.incidence | 83, 94, 127 |
| abstract_inverted_index.included. | 125 |
| abstract_inverted_index.ischaemic | 96, 188 |
| abstract_inverted_index.landscape | 4 |
| abstract_inverted_index.leukaemia | 8 |
| abstract_inverted_index.molecular | 24 |
| abstract_inverted_index.nilotinib | 44, 72, 115, 227, 240, 303 |
| abstract_inverted_index.patients. | 305 |
| abstract_inverted_index.secondary | 89, 146 |
| abstract_inverted_index.toxicity. | 34 |
| abstract_inverted_index.treatment | 141 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Nilotinib, | 18 |
| abstract_inverted_index.associated | 29, 42 |
| abstract_inverted_index.calculated | 65 |
| abstract_inverted_index.developing | 274 |
| abstract_inverted_index.increasing | 283 |
| abstract_inverted_index.inhibitors | 16 |
| abstract_inverted_index.population | 48 |
| abstract_inverted_index.predictive | 52, 300 |
| abstract_inverted_index.real-world | 47 |
| abstract_inverted_index.stratified | 108 |
| abstract_inverted_index.Conclusions | 256 |
| abstract_inverted_index.population. | 157 |
| abstract_inverted_index.therapeutic | 3 |
| abstract_inverted_index.transformed | 12 |
| abstract_inverted_index.twenty-nine | 121 |
| abstract_inverted_index.8.4–16.9%) | 154 |
| abstract_inverted_index.catergories. | 289 |
| abstract_inverted_index.0.97–4.96], | 198 |
| abstract_inverted_index.1.17–5.66], | 178 |
| abstract_inverted_index.1.77–7.20]) | 186 |
| abstract_inverted_index.15.7–26.2%) | 135 |
| abstract_inverted_index.discriminator | 265 |
| abstract_inverted_index.1.91–7.89]). | 206 |
| abstract_inverted_index.cardiotoxicity | 284 |
| abstract_inverted_index.cardiovascular | 32, 275 |
| abstract_inverted_index.stratification | 260 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5110508169 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 11 |
| corresponding_institution_ids | https://openalex.org/I153355300, https://openalex.org/I2801748203 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7599999904632568 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.92110198 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |